Replimune Shares Plummet Amid Regulatory Crisis and Mounting Litigation

Replimune Group Inc. finds itself in a severe crisis, battling significant regulatory setbacks and a growing wave of shareholder litigation. The biotechnology firm’s survival is in question following the U.S. Food and Drug Administration’s (FDA) rejection of its lead drug candidate, RP1. The situation intensifies as a critical deadline for lead plaintiff appointments in class-action lawsuits passes today.

A Deepening Regulatory Quagmire

The company’s regulatory troubles reached a new low after a Type A meeting with the FDA concluded without securing a viable path forward for RP1. The agency maintained its hardline stance, refusing to agree on any accelerated approval pathway for the cancer therapy. This decision, communicated Thursday, triggered a catastrophic intraday sell-off that erased 45% of the stock’s value in a single session, decimating remaining investor confidence in the developmental-stage biotech.

This latest development continues a downward spiral that began months earlier. On July 22, the FDA delivered a devastating blow by issuing a Complete Response Letter for RP1’s Biologics License Application in advanced melanoma. The agency’s rejection was unequivocal, stating that the supporting IGNYTE clinical trial was inadequately designed and lacked sufficient control to demonstrate the treatment’s efficacy.

The market’s reaction to the July announcement was immediate and brutal:
* A single-session collapse of 77%
* Billions in market capitalization wiped out
* The establishment of a firmly entrenched bearish trend

Should investors sell immediately? Or is it worth buying Replimune?

Legal Woes Compound Existential Threat

Beyond its regulatory challenges, Replimune now faces multiple class-action lawsuits alleging the company deliberately misled investors. The suits level serious accusations, including:
* Overstating the probability of the clinical trial’s success
* Failing to disclose critical flaws in the study’s design
* Using heterogeneous patient groups that potentially skewed results

The passing of the September 22 deadline for lead plaintiff motions marks a significant escalation in this legal front. These proceedings represent not just a substantial financial liability but also the near-total erosion of shareholder trust.

With its primary asset stalled indefinitely and legal pressures mounting, the fundamental question remains whether Replimune can navigate a path to recovery.